NCT07182058RecruitingPhase 1/2
Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms
Virtual Remote Assessment of Transcranial Electrical Stimulation for Parkinson's Disease Motor Symptoms
Source: ClinicalTrials.gov · Last updated 27 Jan 2026
Brief summary (registry, in English)
This study tests a new, non-invasive brain stimulation device called Sphere V3.0 to help improve movement problems in people with Parkinson's disease. The device delivers gentle electrical signals to the scalp using small electrodes placed on the head. Participants will use the device at home for 13 minutes each weekday (Monday through Friday) for 3 weeks, then be monitored for another 3 weeks without treatment. The entire study lasts 6 weeks and is conducted virtually through video calls and online assessments. The investigators will measure changes in Parkinson's symptoms using standard rating scales and video recordings of movement tasks like walking and hand tremor tests. Participants will also record videos of their movements at home using their smartphone or computer. The study includes 30 adults aged 18-80 who have been diagnosed with Parkinson's disease and have stable medication for at least 4 weeks. Participants must have reliable internet access and be able to follow the treatment schedule. The main goal is to see if this brain stimulation treatment can reduce motor symptoms like tremor, stiffness, and slowness of movement. The investigators will also check if any improvements last after treatment ends and monitor for any side effects. All participants receive the active device treatment - there is no placebo group. The device has been tested in over 250 people in previous studies with no serious adverse events reported
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 16 Sept 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 1 Mar 2026
- Lead sponsor
- U: The Mind Company
- Diseases
- Parkinson disease
- NCT number
- NCT07182058
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 30
- From 1 Jan 2026 to the primary completion date, 1 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Metallic head/neck implants (excluding dental fillings)
Other illness
- Severe skin conditions at electrode placement sites
- History of epilepsy or seizures (unless technology specifically indicated)
- Recent stroke or traumatic brain injury (within 6 months)
- Severe cognitive impairment preventing treatment understanding
- Any neurological disorders contraindicating transcranial electrical stimulation
Other
- Pregnancy or nursing status
- Current participation in other clinical trials
- Inability to commit to full treatment and follow-up schedule
Who the study is looking for
- Adults 18-80 years with confirmed diagnosis of Parkinson's Disease
- Hoehn \& Yahr stages 1-4
- Stable medication regimen for 4+ weeks prior to enrollment
- Reliable internet access and telehealth capability
- Ability to provide informed consent
- Willingness to comply with treatment protocols and follow-up procedures
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| U LLC Headquarters Coordinator of this site? Confirm its status | Cleveland | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.